Page 6 - Atxs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Atxs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Atxs Today - Breaking & Trending Today

Astria Therapeutics (NASDAQ:ATXS) Coverage Initiated by Analysts at Evercore ISI

Evercore ISI initiated coverage on shares of Astria Therapeutics (NASDAQ:ATXS – Get Rating) in a research note released on Tuesday, The Fly reports. The brokerage issued an outperform rating and a $18.00 target price on the biotechnology company’s stock. ATXS has been the subject of several other research reports. HC Wainwright restated a buy rating […] ....

Millennium Management , Renaissance Technologies , Astria Therapeutics Inc , Jump Financial , Astria Therapeutics , Get Rating , Hereditary Angioedema , Astria Therapeutics Daily , Nasdaq Atxs , Initiated Coverage , Evercore Isi ,

Astria Therapeutics, Inc. (NASDAQ:ATXS) Expected to Announce Earnings of -$0.73 Per Share

Equities analysts predict that Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Rating) will announce earnings per share of ($0.73) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Astria Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.83). Astria Therapeutics […] ....

United States , Northern Trust Corp , Geode Capital Management , Zacks Investment Research , Astria Therapeutics Inc , Blackrock Inc , Oppenheimer Co , Millennium Management , Astria Therapeutics Company Profile Get Rating , Astria Therapeutics , Get Rating , Astria Therapeutic , Investment Research , Capital Management , Trust Corp , Therapeutics Company Profile , Nasdaq Atxs ,

-$0.69 EPS Expected for Astria Therapeutics, Inc. (NASDAQ:ATXS) This Quarter

Equities analysts predict that Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Rating) will post earnings per share (EPS) of ($0.69) for the current quarter, according to Zacks. Zero analysts have issued estimates for Astria Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.75) and the highest estimate coming in at ($0.61). Astria Therapeutics posted […] ....

United States , Morgan Stanley , Goldman Sachs Group Inc , Zacks Investment Research , Astria Therapeutics Inc , Oppenheimer Co , Millennium Management , Astria Therapeutics , Get Rating , Astria Therapeutic , Investment Research , Sachs Group , Nasdaq Atxs ,

Catabasis Pharmaceuticals (NASDAQ:ATXS) Given "Buy" Rating at HC Wainwright

Catabasis Pharmaceuticals (NASDAQ:ATXS – Get Rating)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Friday, TipRanks reports. They presently have a $13.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 83.10% from the stock’s current price. […] ....

United States , Jillc Milne , Michaelr Jirousek , Stevene Shoelson , Northern Trust Corp , Geode Capital Management , Analyst Recommendations For Catabasis Pharmaceuticals , Zacks Investment Research , Catabasis Pharmaceuticals Get Rating , Astria Therapeutics Inc , Blackrock Inc , Oppenheimer Co , Catabasis Pharmaceuticals , Millennium Management , Get Rating , Capital Management , Trust Corp , Nasdaq Atxs , Reiterated Rating , Hc Wainwright ,